Efil, S.C.; Kus, F.; Koylu, B.; Durukan, B.M.; Bayram, S.; Guzel, H.G.; Ozturk, B.; Muglu, H.; Bilici, A.; Kose, F.;
et al. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study. Cancers 2026, 18, 101.
https://doi.org/10.3390/cancers18010101
AMA Style
Efil SC, Kus F, Koylu B, Durukan BM, Bayram S, Guzel HG, Ozturk B, Muglu H, Bilici A, Kose F,
et al. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study. Cancers. 2026; 18(1):101.
https://doi.org/10.3390/cancers18010101
Chicago/Turabian Style
Efil, Safa Can, Fatih Kus, Bahadir Koylu, Bekir Mert Durukan, Selami Bayram, Halil Goksel Guzel, Banu Ozturk, Harun Muglu, Ahmet Bilici, Fatih Kose,
and et al. 2026. "Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study" Cancers 18, no. 1: 101.
https://doi.org/10.3390/cancers18010101
APA Style
Efil, S. C., Kus, F., Koylu, B., Durukan, B. M., Bayram, S., Guzel, H. G., Ozturk, B., Muglu, H., Bilici, A., Kose, F., Alan, O., Karapelit Agitoglu, E., Guner, G., Besen, A. A., Helvaci, K., Araz, M., Kacan, T., Arslan, C., Unal, A.,
... Sendur, M. A. N.
(2026). Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study. Cancers, 18(1), 101.
https://doi.org/10.3390/cancers18010101
